❌

Reading view

↗️

<span>l</span>-Glutamine in combination with first-line gemcitabine and nab-paclitaxel in advanced pancreatic ductal adenocarcinoma: an open-label, single-arm, phase 1 GlutaPanc trial

βœ‡Nature Cancer
By: Jun Gong Β· Hayato Muranaka Β· So Yung Choi Β· Mourad Tighiouart Β· Shrikant Bhute Β· Ezinne R. Aja Β· Jonathan P. Jacobs Β· Aleksandr Stotland Β· Jennifer Van Eyk Β· Omer H. M. Elmadbouh Β· Mouad Edderkaoui Β· Sunao Tanaka Β· Hideki Furuya Β· Arsen Osipov Β· Jeremy Lorber Β· Sandrine Billet Β· Alexzandra Morris Β· Johanna ten Hoeve-Scott Β· Thomas Graeber Β· Stephen J. Pandol Β· Andrew Hendifar Β· Neil A. Bhowmick

Nature Cancer, Published online: 31 August 2026; doi:10.1038/s43018-026-01225-z

In this open-label, single-arm, phase 1 GlutaPanc trial, Gong and colleagues report the safety and feasibility of l-glutamine in participants with advanced pancreatic ductal adenocarcinoma and determine the recommended phase 2 dose of l-glutamine in combination with gemcitabine and nab-paclitaxel.
  •  
  • ↗️
There are no more articles
❌